Next generation histone deacetylase inhibitors: The answer to the search for optimized epigenetic therapies?

Expert Opinion on Drug Discovery

Volumn 6, Issue 4, 2011, Pages 393-404

  Thaler, Florian ^a   Minucci, Saverio ^a,b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

4SC 201; AR 42; belinostat; BYK408740; CG200745; chidamide; CHR 3996; CS055 HBI8000; CUDC 101; depsipeptide; entinostat; FK228; givinostat; HDAC inhibitor; Istodax; ITF 2357; JNJ26481585; LBH589; MGCD0103; mocetinostat; MS 275; panobinostat; PCI 24781; PXD101; resminostat; romidepsin; SAHA; SB939; vorinostat; Zolinza

Indexed keywords

ANTINEOPLASTIC AGENT; AR 42; BELINOSTAT; BENZAMIDE; BENZIMIDAZOL 5 YL ACRYLHYDROXAMIC ACID; BYK 408740; CG 200745; CHIDAMIDE; CHR 3996; ENTINOSTAT; GIVINOSTAT; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; ISTODAX; JNJ 26481585; MOCETINOSTAT; PANOBINOSTAT; PCI 24781; RESMINOSTAT; ROMIDEPSIN; SB 939; SIRTUIN; SORAFENIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; BRAIN CANCER; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; CELL GROWTH; CELL LINE; CELL PROLIFERATION; CELL STRAIN HCT116; CELL STRAIN HL 60; CHROMATIN; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; CUTANEOUS T CELL LYMPHOMA; CYSTITIS; DIARHHEA; DIARRHEA; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTOXICATION; DRUG POTENCY; DRUG RESEARCH; DYSGEUSIA; ENZYME MODIFICATION; EPIGENETICS; FATIGUE; GENETIC TRANSCRIPTION; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HEART VENTRICLE TACHYCARDIA; HISTONE ACETYLATION; HUMAN; IC 50; LARGE CELL LYMPHOMA; LEUKEMIA; LEUKOPENIA; LIVER CELL; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CARCINOMA; PERICARDIAL EFFUSION; PERICARDITIS; PERIPHERAL T CELL LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROSTATE CANCER; QT PROLONGATION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; THROMBOCYTOPENIA; THYROID CARCINOMA; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR VOLUME; VOMITING;

EID: 79953127793     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2011.557660     Document Type: Review

References (85)

1. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev 1999;9(1):40-8 (Pubitemid 29080385)
2. Biancotto C, Frige G, Minucci S. Histone modification therapy of cancer. Adv Genet 2010;6:341-86
3. Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation? EMBO J 2000;19(6):1176-9 (Pubitemid 30151013)
4. Choudhary C, Kumar C, Gnad F, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009;325(5942):834-40
5. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6(1):38-51 (Pubitemid 43054973)
6. Mercurio C, Minucci S, Pelicci PG. Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol Res 2010;62(1):18-34
7. Tan J, Cang S, Ma Y, et al. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents.J Hematol Oncol 2010;3:5
8. Copeland A, Buglio D, Younes A. Histone deacetylase inhibitors in lymphoma. Curr Opin Oncol 2010;22(5):431-6
9. Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 2009;15(12):3958-69
10. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009;27(32):5459-68
11. Glaser KB. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 2007;74(5):659-71 (Pubitemid 47096639)
12. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 2007;26(9):1351-6 (Pubitemid 46328465)
13. Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009:5410-17
14. Gottlicher M. Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. Ann Hematol 2004;83(Suppl 1):S91-2
15. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, et al. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 2008;34(3):206-22
16. Blaheta RA, Cinatl J Jr. Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 2002;22(5):492-511
17. Graham JS, Kaye SB, Brown R. The promises and pitfalls of epigenetic therapies in solid tumours. Eur J Cancer 2009;45(7):1129-36
18. Marsoni S, Damia G, Camboni G. A work in progress: the clinical development of histone deacetylase inhibitors. Epigenetics 2008;3(3):164-71
19. Botrugno OA, Santoro F, Minucci S. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. Cancer Lett 2009;280(2):134-44
20. Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008;269(1):7-17
21. Nolan L, Johnson PW, Ganesan A, et al. Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? Br J Cancer 2008;99(5):689-94
22. Mahboobi S, Dove S, Sellmer A, et al. Design of chimeric histone deacetylase-and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.J Med Chem 2009;52(8):2265-79
23. Cai X, Zhai HX, Wang J, et al. Discovery of 7-(4-(3-ethynylphenylamino)- 7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanam ide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J Med Chem 2010;53(5):2000-9
24. Lai CJ, Bao R, Tao X, et al. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res 2010;70(9):3647-56
25. Shimizu T, Tolcher AW, LoRusso P, et al. 364 The first-in-human, first-in-class study of CUDC-101, a multi-targeted inhibitor of HDAC, EGFR, and HER2: a Phase I study in patients with advanced cancer. Eur J Cancer Suppl 2010;8(7):115
26. Andersen JB, Factor VM, Marquardt JU, et al. An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. Sci Transl Med 2010;2(54):54ra77
27. Altucci L, Minucci S. Epigenetic therapies in haematological malignancies: searching for true targets. Eur J Cancer 2009;45(7):1137-45
28. Gargiulo G, Minucci S. Epigenomic profiling of cancer cells. Int J Biochem Cell Biol 2009;41(1):127-35
29. Bradner JE, West N, Grachan ML, et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010;6(3):238-43
30. Elaut G, Rogiers V, Vanhaecke T. The pharmaceutical potential of histone deacetylase inhibitors. Curr Pharm Des 2007;13(25):2584-620 (Pubitemid 47430437)
31. Ryan QC, Headlee D, Acharya M, et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005;23(17):3912-22 (Pubitemid 46218694)
32. Saito A, Yamashita T, Mariko Y, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 1999;96(8):4592-7 (Pubitemid 29190381)
33. Wang H, Dymock BW. New patented histone deacetylase inhibitors. Expert Opin Ther Pat 2009;19(12):1727-57
34. Yeo P, Xin L, Goh E, et al. Development and validation of high-performance liquid chromatography-tandem mass spectrometry assay for 6-(3-benzoyl-ureido)-hexanoic acid hydroxyamide, a novel HDAC inhibitor, in mouse plasma for pharmacokinetic studies. Biomed Chromatogr 2007;21(2):184-9
35. Sangthongpitag K, Wang H, Yeo P, et al. ADME and PK/PD attributes of SB939, a potent orally active HDAC inhibitor Eur J Cancer Suppl 2006;4(12):53
36. Novotny-Diermayr V, Sangthongpitag K, Hu CY, et al. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther 2010;9(3):642-52
37. Yong W, Goh B, Toh H, et al. Phase I study of SB939 three times weekly for 3 weeks every 4 weeks in patients with advanced solid malignancies. J Clin Oncol 2009;27(15):abstract 2560
38. Mandl-Weber S, Meinel FG, Jankowsky R, et al. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. Br J Haematol 2010;149(4):518-28
39. Brunetto AT, Ang JE, Lal R, et al. A first-in-human phase I study of 4SC-201, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumors [abstr 3530]. J Clin Oncol 2009;27:15s
40. Hauns B, Mais A, Jankowsky R, et al. Centralised analysis of phase I ECG dataset of resminostat, a new oral histone deacetylase inhibitor (HDACi). Eur J Cancer Suppl 2010;8(7):172
41. Bitzer M, Horger M, Ebert M, et al. First clinical data of resminostat, a novel oral histone deacetylase (HDAC) inhibitor, in patients with hepatocellular carcinoma (HCC)-the SHELTER Study. 'Viszeralmedizin 2010' Symposium; organized by the German Gastroenterology (DGVS) and Visceral Surgery Associations (DGAV). Stuttgart, Germany; 2010. p. P432
42. Arts J, King P, Marien A, et al. JNJ-26481585, a novel 'second-generation' oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res 2009;15(22):6841-51
43. Hickson I, King P, Marien A, et al. Preclinical assessment of the HDAC inhibitor JNJ-26481585: potent in vivo activity across a broad spectrum of human tumor xenografts. AACR Meeting Abstracts 2010;2010:5441
44. Postel-Vinay S, Kristeleit R, Fong P, et al. Preliminary results of an open-label phase I pharmacokinetic/pharmacodynamic study of JNJ26481585: early evidence of antitumor activity. J Clin Oncol 2009;27(20 Suppl 15S):e13504
45. Donald A, Belfield A, Day F, et al. The discovery and Anti-Tumor Activity CHR-3996-A Novel, Orally Available Inhibitor of Class 1 Histone Deacetylases. EFMC-ISMC (European Federation for Medicinal Chemistry) 2010, XXIst International Symposium on Medicinal Chemistry. Brussels 2010:PC 365
46. Banerji U, van Doorn L, Papadatos-Pastos D, et al. A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of CHR-3996, a class 1 selective histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors. J Clin Oncol 2010;28(15 Suppl):2552
47. Lu Q, Wang DS, Chen CS, et al. Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem 2005;48(17):5530-5 (Pubitemid 41209250)
48. Lucas DM, Alinari L, West DA, et al. The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. PLoS One 2010;5(6):e10941
49. Kulp SK, Chen CS, Wang DS, et al. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Clin Cancer Res 2006;12(17):5199-206 (Pubitemid 44453349)
50. Cheng H, Liu Z, Kulp SK, et al. Preclinical pharmacokinetic studies with s-HDAC-42 (NSC 736012), an inhibitor of histone deacetylase, by LC-MS/MS. Proc Am Assoc Cancer Res 2006;47:abstract 3091
51. Cheng H, Jones W, Wei X, et al. Preclinical pharmacokinetics studies of R-and S-enantiomers of the histone deacetylase inhibitor, HDAC-42 (NSC 731438), in the rat. Proc Am Assoc Cancer Res 2006;47:abstract 686
52. Oh ET, Park MT, Choi BH, et al. Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells. Invest New Drugs 2010 published online 27 October 2010, doi:10.1007/s10637-010-9568-2
53. Hyun Y-L, Kim HJ, Kim YE, et al. Preclinical studies of CG200745, novel histone deacetylase inhibitor discovered using structure-based drug discovery technologies. AACR Meeting Abstracts 2009 2009;2009:4561
54. Lee CS, Kang SK, Seo HS, et al. DMPK and early tox study of a novel HDAC inhibitor, CG200745. AACR Meeting Abstracts 2008 2008;2008:2617
55. Liu L, Chen B, Qin S, et al. A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells. Biochem Biophys Res Commun 2010;392(2):190-5
56. Dong M, Ning Z, Newman MJ, et al. Phase I study of chidamide (CS055/HBI-8000), a novel histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas [abstract 3529]. J Clin Oncol 2009;27:15s
57. Prince HM, Bishton MJ, Johnstone RW. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol 2009;5(5):601-12
58. Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 2009;280(2):233-41
59. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007;25(1):84-90 (Pubitemid 46087907)
60. Lahm A, Paolini C, Pallaoro M, et al. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci USA 2007;104(44):17335-40 (Pubitemid 350219843)
61. Finnin MS, Donigian JR, Cohen A, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999;401(6749):188-93 (Pubitemid 29436325)
62. Cronin CN, Hilgers M, Knuth ME, et al. Crystallization of histone deacetylase 2. US7507552; 2009
63. Bottomley MJ, Lo Surdo P, Di Giovine P, et al. Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J Biol Chem 2008;283(39):26694-704
64. Schuetz A, Min J, Allali-Hassani A, et al. Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J Biol Chem 2008;283(17):11355-63
65. Somoza JR, Skene RJ, Katz BA, et al. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 2004;12(7):1325-34 (Pubitemid 38900774)
66. Vannini A, Volpari C, Filocamo G, et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci USA 2004;101(42):15064-9 (Pubitemid 39391719)
67. Balasubramanian S, Steggerda S, Sirisawad M, et al. The Histone Deacetylase-8 (HDAC8) Selective Inhibitor PCI-34051 Decreases Interleukin-1 Beta Secretion in vitro and Reduces Inflammation in vivo 50th ASH Annual Meeting and Exposition; 2009; San Francisco: American Society of Hematology; 2009;abstract 2581
68. Moradei O, Paquin I, Leit S, et al. Inhibitors of histone deacetylase. WO2005030704; 2005
69. Wilson KJ, Witter DJ, Grimm JB, et al. Phenylglycine and phenylalanine derivatives as potent and selective HDAC1 inhibitors (SHI-1). Bioorg Med Chem Lett 2008;18(6):1859-63
70. Witter DJ, Harrington P, Wilson KJ, et al. Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2). Bioorg Med Chem Lett 2008;18(2):726-31
71. Methot JL, Chakravarty PK, Chenard M, et al. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2). Bioorg Med Chem Lett 2008;18(3):973-8 (Pubitemid 351179353)
72. Bressi JC, Jennings AJ, Skene R, et al. Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett 2010;20(10):3142-5
73. Tessier P, Smil DV, Wahhab A, et al. Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett 2009;19(19):5684-8
74. Itoh Y, Suzuki T, Miyata N. Isoform-selective histone deacetylase inhibitors. Curr Pharm Des 2008;14(6):529-44 (Pubitemid 351516877)
75. Butler KV, Kozikowski AP. Chemical origins of isoform selectivity in histone deacetylase inhibitors. Curr Pharm Des 2008;14(6):505-28 (Pubitemid 351516876)
76. Salisbury CM, Cravatt BF. Activity-based probes for proteomic profiling of histone deacetylase complexes. Proc Natl Acad Sci USA 2007;104(4):1171-6 (Pubitemid 46183977)
77. Bantscheff M, Eberhard D, Abraham Y, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007;25(9):1035-44 (Pubitemid 47517638)
78. Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature 2010;468(7327):1067-73
79. Zhang B, Strauss AC, Chu S, et al. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 2010;17(5):427-42
80. Yu Y, Zeng P, Xiong J, et al. Epigenetic drugs can stimulate metastasis through enhanced expression of the pro-metastatic Ezrin gene. PLoS One 2010;5(9):e12710
81. Wang Y, Zhang H, Chen Y, et al. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 2009;138(4):660-72
82. Bandyopadhyay D, Mishra A, Medrano EE. Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway. Cancer Res 2004;64(21):7706-10 (Pubitemid 39446901)
83. Fantin VR, Loboda A, Paweletz CP, et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res 2008;68(10):3785-94
84. Stimson L, La Thangue NB. Biomarkers for predicting clinical responses to HDAC inhibitors. Cancer Lett 2009;280(2):177-83
85. Scott GK, Marx C, Berger CE, et al. Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6. Mol Cancer Res 2008;6(7):1250-8